Creo Medical Group PLC
LSE:CREO
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
UK |
Creo Medical Group PLC
LSE:CREO
|
129.1m GBP | -3.8 | ||
US |
Abbott Laboratories
NYSE:ABT
|
179.5B USD | 28.1 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
141.9B USD | 73.6 | ||
US |
Stryker Corp
NYSE:SYK
|
125.6B USD | 29.9 | ||
IE |
Medtronic PLC
NYSE:MDT
|
112.4B USD | 20 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
110.8B USD | 46.6 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.9B USD | 37.2 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
59B EUR | 27 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
54B USD | 30.1 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
51.8B USD | 78.8 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
369.6B CNY | 27.9 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.